Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
8 August 2022 |
Main ID: |
EUCTR2017-003090-34-DE |
Date of registration:
|
15/11/2018 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
A study testing how BI 655130 works in patients with fistulizing Crohn’s Disease
|
Scientific title:
|
Mechanism of Action and Clinical Effect of BI 655130 in Patients with fistulizing Crohn’s Disease - BI 655130 treatment of fistulizing CD |
Date of first enrolment:
|
18/02/2019 |
Target sample size:
|
28 |
Recruitment status: |
Not Recruiting |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-003090-34 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: yes Randomised: yes Open: no Single blind: no Double blind: yes Parallel group: yes Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: no Placebo: yes Other: no Number of treatment arms in the trial: 2
|
Phase:
|
Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): no
|
|
Countries of recruitment
|
Austria
|
Belgium
|
Denmark
|
Germany
|
Hungary
|
Korea, Republic of
|
Netherlands
|
Spain
|
Contacts
|
Name:
|
CT Disclosure & Data Transparency
|
Address:
|
Binger Straße 173
55216
Ingelheim am Rhein
Germany |
Telephone:
|
+18002430127 |
Email:
|
clintriage.rdg@boehringer-ingelheim.com |
Affiliation:
|
Boehringer Ingelheim Pharma GmbH & Co. KG |
|
Name:
|
CT Disclosure & Data Transparency
|
Address:
|
Binger Straße 173
55216
Ingelheim am Rhein
Germany |
Telephone:
|
+18002430127 |
Email:
|
clintriage.rdg@boehringer-ingelheim.com |
Affiliation:
|
Boehringer Ingelheim Pharma GmbH & Co. KG |
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: Each patient of Screening Cohort and Study Cohort must meet all of the following inclusion criteria to be included into the trial: 1. 18-75 years at date of signing informed consent 2. Diagnosis of clinical Crohn´s Disease = 3 months prior to screening by clinical and endoscopic evidence and corroborated by a histopathology report 3. Has = 1 perianal active* fistula(s) with clinical indication for seton drainage (= 4 weeks duration before enrolment, as a complication of CD) **. * Criteria for Active Fistula: As per clinical evaluation: Presence of spontaneous drainage or drainage after gentle finger compression at the external openings & as confirmed by radiological (MRI) exploration . ** Patients who are screened with a seton drainage in place are eligible provided the drainage has not been in place for > 3 months and the patient meets the rest of the eligibility criteria 5. Additional enterocutaneous or abdominal fistulas are permitted (except rectovaginal fistulas) 6. Absent, mild or moderate clinical activity with CDAI < 250. CDAI is not applicable for Screening Cohort. 7. Demonstrated in the past inadequate response or loss of response or have had unacceptable side effects with approved doses of at least one of the following compounds: Immunesuppressive agents (e.g. thiopurines, methotrexate), TNF? antagonists (e.g. infliximab, adalimumab, certolizumab pegol; or respective biosimilars), vedolizumab, ustekinumab, azathioprine and / or antibiotics 8. Patients with family history of colorectal cancer or personal history of increased colorectal cancer risk must have had a negative ileocolorectal cancer screening within <1 year prior to screening per local guidance (otherwise to be done during screening ileocolonoscopy). 9. Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 20 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 8
Exclusion criteria: No exclusion criteria are applicable for the Screening Cohort. Following exclusion criteria are applicable for the Study Cohort: 1. Complications of Crohn’s Disease such as symptomatic strictures, functional stenosis distal from fistula(s), short gut syndrome, or any other manifestation that might require surgery, could preclude the use of the PDAI and CDAI to assess response to therapy, or would possibly confound the evaluation of benefit from treatment with BI 655130 2. Rectovaginal fistulas 3. Anticipated to require surgical intervention for CD, including any fistula surgical procedures (except seton drainage). See Table 4.2.2.2:1 for a detailed list of restricted interventions 4. Has an abscess that the investigator feels requires drainage beyond fistula drainage with a seton (based on either clinical assessment or MRI) 5. Any kind of bowel resection or diversion within 6 months or any other intraabdominal surgery within 3 months prior to screening. 6. Ileostomy, colostomy or known fixed symptomatic stenosis of the intestine at screening. 7. Evidence of colonic mucosal dysplasia or colonic adenomas, unless properly removed (properly according to the investigator’s assessment) 8. Faecal Microbiota transplant (FMT) within 6 months prior to randomization
Further criteria apply.
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
Fistulizing Crohn’s Disease MedDRA version: 20.0
Level: LLT
Classification code 10075465
Term: Fistulizing Crohn's disease
System Organ Class: 100000004856
|
Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
|
Intervention(s)
|
Product Name: BI 655130 Product Code: BI 655130 Pharmaceutical Form: Solution for infusion INN or Proposed INN: Spesolimab Current Sponsor code: BI 655130 Other descriptive name: MONOCLONAL ANTIBODY ANTI-IGG1 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 60- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use
|
Primary Outcome(s)
|
Main Objective: - To explore the pathomechanisms involved in the generation and healing of CD associated perianal fistulas - To understand the MoA of BI 655130 in patients with CD and draining perianal fistulas
|
Secondary Objective: -
|
Primary end point(s): 1) Total number of deregulated genes at week 4
|
Timepoint(s) of evaluation of this end point: 1) week 4
|
Secondary Outcome(s)
|
Timepoint(s) of evaluation of this end point: 1) week 12 2) week 12 3) week 12
|
Secondary end point(s): 1) Proportion of patients with perianal fistula response at week 12 2) Proportion of patients with perianal fistula remission at week 12 3) Proportion of patients with combined perianal fistula remission at week 12
|
Secondary ID(s)
|
1368-0008
|
2017-003090-34-AT
|
Source(s) of Monetary Support
|
Boehringer Ingelheim Pharma GmbH & Co. KG
|
Ethics review
|
Status: Approved
Approval date: 25/01/2019
Contact:
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|